Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BAT1706 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BAT1706 | BAT-1706|BAT 1706 | VEGFA Antibody 7 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04164199 | Phase III | Lenvatinib + Tislelizumab Sitravatinib LBL-007 + Tislelizumab Tislelizumab + Zanidatamab Pamiparib + Tislelizumab Fruquintinib + Tislelizumab BGB-A425 + Tislelizumab BGBA1217 + Tislelizumab BGB-15025 BGB-A425 + LBL-007 + Tislelizumab Tislelizumab BGB-15025 + Tislelizumab BGB-A445 + Tislelizumab Sitravatinib + Tislelizumab Pamiparib + Temozolomide Zanidatamab BAT1706 + Tislelizumab BAT1706 Pamiparib | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | Active, not recruiting | USA | TUR | POL | NZL | ITA | FRA | AUS | 6 |